super slot game
GREENSBORO, N.C.--(BUSINESS WIRE)--Nov 21, 2024-- Tanger® (NYSE: SKT) , a leading owner and operator of outlet and open-air retail shopping destinations, has earned additional recognition from national certification programs for taking steps to address climate change and enhance well-being at its centers. With these actions, Tanger now has achieved LEED certification for 20 centers, or 58% of its owned and managed portfolio by gross leasable area. Additionally, Tanger has expanded recognition of its centers as StormReady® and WELL Health-Safety Rated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121075293/en/ Tanger Outlets Nashville is the 20th Tanger shopping center to achieve LEED certification. The open-air outlet center in Nashville, Tennessee, which opened last year, was designed with extensive features – like on-site solar energy infrastructure – that help to address the impacts of climate change and enhance community well-being, in support of Tanger’s overall sustainability commitments. Photo credit: Tanger “As a key part of Tanger’s mission, we strive to deliver the best experience for all who shop, dine and work in and around our shopping destinations. Providing for the well-being of our communities through sustainable, healthy operations is a vital part of that commitment,” said Jessica Norman, Executive Vice President, General Counsel and Secretary for Tanger, who oversees the company’s environmental, social, and governance program and disclosures. “These recognitions from respected benchmark programs verify the steps we’ve taken to prepare our centers for the impacts of a changing climate and have positioned us to better serve the needs of our communities, in keeping with our core value to consider our communities first.” LEED Tanger Outlets Nashville in Tennessee has achieved LEED Silver® certification for Building Design and Construction (BD+C): Core and Shell Development from the U.S. Green Building Council. LEED® is the world's most widely used green building rating system, recognizing best-in-class building strategies and practices. With this certification, Tanger Nashville becomes the 20th shopping center in Tanger’s portfolio to be certified in the LEED program and Tanger’s third retail development to achieve BD+C certification for addressing carbon impacts in the design and construction process. Tanger Nashville’s transformational design supports sustainability through on-site solar energy production, water use reduction systems, low-emitting materials, lighting controls, electric vehicle charging, and more. The center fosters engagement and well-being through ease of access, walkability, green and gathering spaces, an extensive mural arts program, and restaurants, retail brands, and experiences that celebrate the local culture and community. Opened in October 2023, the development has also helped to revitalize the Southeast Nashville community that surrounds it, fueling job creation, economic health, and business growth in the area. Earlier this year, the Nashville chapter of the Urban Land Institute recognized Tanger Nashville with a 2024 Excellence in Development Award for being one of the best and most innovative projects in the region and for its positive impacts on the community. Tanger Nashville will next pursue LEED Gold® for Operations and Maintenance (O+M) certification, as will Bridge Street Town Centre, Tanger’s open-air lifestyle shopping destination in Huntsville, Alabama. Tanger has 18 other shopping centers that have achieved LEED Gold O+M certification (one of which also achieved BD+C certification), reflecting Tanger’s deep commitment to best-in-class, sustainable operations across its portfolio. StormReady Tanger has also taken steps to mitigate the potential impacts of severe weather on its operations, for the benefit of all who work and shop at its centers. Tanger partners with the U.S. Department of Commerce and National Weather Service to ensure its shopping centers are “StormReady” and has been recognized as a Weather-Ready Nation Ambassador of the National Oceanic and Atmospheric Association. These programs help communities strengthen local safety programs and preparation skills needed to protect lives and property in extreme weather and water events. The scenario-specific Weather-Ready plans Tanger maintains at its centers have helped its local team members remain safe and mitigate property damage during events like this year’s devastating hurricanes. In the wake of Hurricane Helene, Tanger’s center in Asheville, North Carolina, was well prepared to support the community, hosting emergency responders on-site and quickly restoring business operations to serve residents and business partners. WELL Health and Safety As part of its commitment to the well-being of people at its centers, Tanger achieved and has maintained the WELL Health-Safety Rating for Facility Operations and Management for all the shopping centers it owned and managed in the U.S. in 2022. This year, Tanger Outlets Nashville also achieved this Rating, and the two newest additions to Tanger’s portfolio, in Huntsville, AL, and Asheville, NC, are expected to achieve it in 2025. A component of the International WELL Building Institute’s WELL Building Standard, the WELL Health-Safety Rating recognizes owners and operators like Tanger that prioritize the health and safety of their team members, visitors, and stakeholders. Tanger also participates in the WELL at Scale program to maintain its WELL Ratings more efficiently and benchmark its health and well-being efforts across the portfolio. For more information about Tanger’s commitments to people, planet, and communities, please see the company’s 2023 Environmental, Social, and Governance Report, available on its investor relations website at investors.tanger.com/corporate-responsibility . About Tanger® Tanger Inc . (NYSE: SKT) is a leading owner and operator of outlet and open-air retail shopping destinations, with over 43 years of expertise in the retail and outlet shopping industries. Tanger’s portfolio of 38 outlet centers, one adjacent managed center, and one open-air lifestyle center includes over 15 million square feet well positioned across tourist destinations and vibrant markets in 20 U.S. states and Canada. A publicly traded REIT since 1993, Tanger continues to innovate the retail experience for its shoppers with over 3,000 stores operated by more than 700 different brand name companies. For more information on Tanger, call 1-800-4TANGER or visit tanger.com . The Company uses, and intends to continue to use, its Investor Relations website, which can be found at investors.tanger.com , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Additional information about the Company can also be found through social media channels. The Company encourages investors and others interested in the Company to review the information on its Investor Relations website and on social media channels. The information contained on, or that may be accessed through, our website or social media platforms is not incorporated by reference into, and is not a part of, this document. Forward-Looking Statements This release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, are generally identifiable by use of the words "believe," "expect," "intend," "anticipate," or similar expressions. These forward-looking statements are based upon the beliefs and expectations of management at the time of this release. You should not rely on forward-looking statements since they involve known and unknown risks and uncertainties which could cause actual results to differ materially from those presented in the forward-looking statements. Please refer to the documents filed by the Company with the SEC, including specifically the "Risk Factors" sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's other filings with the SEC, which identify additional factors that could cause actual results to differ from those contained in forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as may be required by law. View source version on businesswire.com : https://www.businesswire.com/news/home/20241121075293/en/ CONTACT: Media Contact Kasie Wilson KWT Global Tanger@kwtglobal.com Investor Relations Contact Doug McDonald SVP, Treasurer and Investments (336) 856-6066 TangerIR@tanger.com KEYWORD: NORTH CAROLINA TENNESSEE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLIMATE CHANGE OTHER RETAIL COMMERCIAL BUILDING & REAL ESTATE CONSTRUCTION & PROPERTY REIT PROFESSIONAL SERVICES ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) GREEN TECHNOLOGY RETAIL ENVIRONMENT SUSTAINABILITY SOURCE: Tanger Copyright Business Wire 2024. PUB: 11/21/2024 04:15 PM/DISC: 11/21/2024 04:15 PM http://www.businesswire.com/news/home/20241121075293/enZuora Reports Third Quarter Fiscal 2025 ResultsFive leaders of Mohila Awami League have been arrested in a case filed over the attacks on Anti-Discrimination Student Movement at Pallabi in the capital. They were arrested conducting raids on Friday night. The arrested were Pallabi Thana's Ward No. 6 Mohila Awami League general secretary Sabina Yasmin Juthi, organizing secretary Rita Aktere, vice-president Nazma Akter Sathi, assistant organizing secretary Khadija Begum and ward Mohila Awami League leader Bably Begum. Pallabi Police Station sources said in the afternoon of August 4 last, student Md Abid joined the movement along with students and people in front of Popular-2 Diagnostic Centre at Mirpur Section 10. Leaders of different levels of Awami League and its front organisations launched attacks on students and people with local arms and pistols. At that time, Abid was seriously injured when a bullet hit on his right eye. He was given treatment at the National Opthalmogy Institute and Hospital. In connection with the incident, the injured Abid's brother Jinnat Saidee filed a case with Pallabi Police Station on November 12. After examining CCTV footage, police arrested Sabina Yasmin Juthi, Rita Akter, Nazma Akter Sathi and Khadija Begum with the help of information technology. END/SZA
As suspense lingers over the next Chief Minister of Maharashtra , Shiv Sena (UBT) leader Anant Dubey on Saturday criticised the Mahayuti alliance , stating that while they have secured a clear mandate, they remain undecided on the leadership. Speaking to ANI, Dubey questioned, "Do they (Mahayuti) want Central rule in Maharashtra?" "Elections were held on November 20, and the results were announced on November 23. It has been a week since then, yet there is no government in the state. They have a clear mandate but don't know who the CM will be. When will they start addressing the needs of the people? We fail to understand their plan of action. In every other state, they declared the CM face on time, so why is Maharashtra being treated differently?" he said. Reports on Friday suggested that caretaker Chief Minister Eknath Shinde was "upset" and had travelled to his native village amid the delay in forming the government. However, Shiv Sena leader Uday Samant dismissed these claims, clarifying that Shinde would return soon and that the next cabinet would be finalised shortly. "The reports of him being upset are media speculations. We were with Eknath Shinde until early morning. He will return tomorrow. Meetings are not limited to physical gatherings; they can also happen via video conferencing or mobile. As Eknath Shinde has stated, the Maharashtra cabinet will be finalised soon," Uday Samant told ANI. Marketing Marketing & Sales Strategies for Startups: From Concept to Conversion By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Office Productivity Advanced Excel Course - Financial Calculations & Excel Made Easy By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Marketing Digital Marketing Masterclass by Neil Patel By - Neil Patel, Co-Founder and Author at Neil Patel Digital Digital Marketing Guru View Program Finance A2Z Of Finance: Finance Beginner Course By - elearnmarkets, Financial Education by StockEdge View Program Web Development C++ Fundamentals for Absolute Beginners By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) Tabnine AI Masterclass: Optimize Your Coding Efficiency By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance AI and Generative AI for Finance By - Hariom Tatsat, Vice President- Quantitative Analytics at Barclays View Program Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development Advanced Java Mastery: Object-Oriented Programming Techniques By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development JavaScript Essentials: Unlock AI-Driven Insights with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) ChatGPT Mastery from Zero to Hero: The Complete AI Course By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Leadership Crafting a Powerful Startup Value Proposition By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program On Thursday night, Maharashtra's caretaker CM Eknath Shinde, Deputy CM Devendra Fadnavis , NCP leader Ajit Pawar , and other Mahayuti leaders met Union Home Minister Amit Shah and BJP National President JP Nadda in the national capital. Following the meeting, Shinde described it as "good and positive" and hinted at another meeting where a final decision on the Chief Minister's post is expected. "The meeting was good and positive. This was the first meeting. We had discussions with Amit Shah and JP Nadda. There will be another Mahayuti meeting in Mumbai, where a decision on the Chief Minister will be taken," Shinde said. The Maharashtra Assembly election results, declared on November 23, saw the BJP-led Mahayuti alliance secure a landslide victory. Despite the clear majority, the ruling alliance is yet to announce its Chief Minister. (You can now subscribe to our Economic Times WhatsApp channel )
The Latest: Matt Gaetz withdraws his name from consideration as Trump’s attorney general
Lowe’s Companies ( NYSE:LOW – Free Report ) had its price objective upped by DA Davidson from $240.00 to $270.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a neutral rating on the home improvement retailer’s stock. DA Davidson also issued estimates for Lowe’s Companies’ FY2025 earnings at $11.84 EPS and FY2026 earnings at $12.60 EPS. A number of other brokerages have also issued reports on LOW. Truist Financial boosted their target price on Lowe’s Companies from $306.00 to $307.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Morgan Stanley increased their target price on Lowe’s Companies from $250.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. UBS Group lifted their target price on Lowe’s Companies from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, August 21st. Gordon Haskett reduced their price target on shares of Lowe’s Companies from $245.00 to $240.00 and set a “hold” rating on the stock in a research report on Wednesday, August 21st. Finally, Bank of America raised their price objective on shares of Lowe’s Companies from $275.00 to $305.00 and gave the company a “buy” rating in a research note on Friday, October 11th. Ten research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Lowe’s Companies presently has a consensus rating of “Moderate Buy” and an average price target of $277.92. Read Our Latest Analysis on LOW Lowe’s Companies Stock Performance Lowe’s Companies Increases Dividend The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 6th. Stockholders of record on Wednesday, October 23rd were given a $1.15 dividend. The ex-dividend date of this dividend was Wednesday, October 23rd. This is a positive change from Lowe’s Companies’s previous quarterly dividend of $0.15. This represents a $4.60 annualized dividend and a dividend yield of 1.74%. Lowe’s Companies’s dividend payout ratio is currently 38.37%. Insider Activity In related news, CAO Dan Clayton Griggs, Jr. sold 6,769 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $248.82, for a total transaction of $1,684,262.58. Following the sale, the chief accounting officer now owns 9,383 shares in the company, valued at approximately $2,334,678.06. This trade represents a 41.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, EVP Margrethe R. Vagell sold 5,730 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $271.45, for a total transaction of $1,555,408.50. Following the sale, the executive vice president now owns 13,214 shares in the company, valued at approximately $3,586,940.30. This trade represents a 30.25 % decrease in their position. The disclosure for this sale can be found here . Company insiders own 0.26% of the company’s stock. Institutional Trading of Lowe’s Companies A number of hedge funds have recently bought and sold shares of LOW. Bamco Inc. NY raised its stake in Lowe’s Companies by 10.3% during the first quarter. Bamco Inc. NY now owns 216,958 shares of the home improvement retailer’s stock worth $55,266,000 after purchasing an additional 20,181 shares during the period. Plato Investment Management Ltd raised its stake in Lowe’s Companies by 655.9% during the first quarter. Plato Investment Management Ltd now owns 6,304 shares of the home improvement retailer’s stock worth $1,606,000 after purchasing an additional 5,470 shares during the period. HM Payson & Co. raised its stake in Lowe’s Companies by 1.1% during the third quarter. HM Payson & Co. now owns 215,651 shares of the home improvement retailer’s stock worth $58,409,000 after purchasing an additional 2,322 shares during the period. Daymark Wealth Partners LLC raised its stake in Lowe’s Companies by 12.7% during the second quarter. Daymark Wealth Partners LLC now owns 25,569 shares of the home improvement retailer’s stock worth $5,637,000 after purchasing an additional 2,889 shares during the period. Finally, AMF Tjanstepension AB raised its stake in Lowe’s Companies by 14.4% during the third quarter. AMF Tjanstepension AB now owns 159,742 shares of the home improvement retailer’s stock worth $43,290,000 after purchasing an additional 20,123 shares during the period. Institutional investors and hedge funds own 74.06% of the company’s stock. About Lowe’s Companies ( Get Free Report ) Lowe’s Companies, Inc, together with its subsidiaries, operates as a home improvement retailer in the United States. The company offers a line of products for construction, maintenance, repair, remodeling, and decorating. It also provides home improvement products, such as appliances, seasonal and outdoor living, lawn and garden, lumber, kitchens and bath, tools, paint, millwork, hardware, flooring, rough plumbing, building materials, décor, and electrical. Featured Stories Receive News & Ratings for Lowe's Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lowe's Companies and related companies with MarketBeat.com's FREE daily email newsletter .Gadodiamide Injection Market Outlook and Future Projections for 2030Biliary Tract Cancer Pipeline Therapeutics Assessment Report 2024 (Updated) 11-30-2024 01:32 PM CET | Health & Medicine Press release from: DelveInsight Business Research LLP Biliary Tract Cancer Pipeline DelveInsight's, "Biliary Tract Cancers Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers Pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Biliary Tract Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Biliary Tract Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Biliary Tract Cancer Pipeline Report •In November 2024:- Unicancer- This is a Phase 3, multicentre, randomised, open-label trial to evaluate whether the introduction of molecular targeted therapy (MTT) as maintenance after 4 cycles of standard-of-care first-line systemic therapy (1L SoC) is superior to continuation of 1L-SoC in the treatment of patients with ABC. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, and (ii) a randomised comparative trial. •In November 2024:- AstraZeneca- A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers •DelveInsight's Biliary Tract Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for treatment. •The leading Biliary Tract Cancer Companies such as Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others. •Promising Biliary Tract Cancer Therapies such as Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others. Stay ahead with the most recent pipeline outlook for Biliary Tract Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Biliary Tract Cancer Treatment Drugs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Biliary Tract Cancer Emerging Drugs Profile •MRG 002: Miracogen MRG 002, is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. An open-label, single-arm, multi-center, phase II Clinical Study of MRG002 are conducted by Miracogen for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic biliary tract cancer. MRG002 is administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle). •Disitamab vedotin: Yantai Rongchang Pharmaceutical Disitamab Vedotin is an antibody-drug conjugate with a drug structure consisting of three parts Anti-human epidermal growth factor receptor 2 extracellular domain (HER2 ECD) antibody; Linker (MC-Val-Cit-PAB, Linker); and Cytotoxic Monomethyl Auristatin E (Monomethyl Auristatin E, MMAE). This product is white to light yellow loose body, after reconstitution, it is colorless to light yellow clear liquid. •Envafolimab: Alphamab Oncology Envafolimab is a PD-L1 single-domain antibody Fc fusion protein independently developed by Alphamab. Based on the unique design, Envafolimab has advantages in safety, convenience and compliance, and can be used for patients who are not suitable for intravenous infusion with a lower medical cost. On March 30, 2020, Alphamab, 3D Medicines and Simcere reached a three-way strategic collaboration. Alphamab, as the original research party, is responsible for production and quality, 3D Medicines is responsible for global clinical development in the field of oncology, registration and commercialization abroad, and Simcere is responsible for the exclusive commercial promotion of the product in mainland China. •DKN-01: Leap Therapeutics DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and has an important role in promoting tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. Explore groundbreaking therapies and clinical trials in the Biliary Tract Cancer Pipeline. Access DelveInsight's detailed report now! @ New Biliary Tract Cancer Drugs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration •Intravenous •Subcutaneous •Oral •Intramuscular Products have been categorized under various Molecule types such as •Monoclonal antibody •Small molecule •Peptide Unveil the future of Biliary Tract Cancer treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Biliary Tract Cancer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Scope of the Biliary Tract Cancer Pipeline Report •Coverage- Global •Biliary Tract Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination •Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III •Biliary Tract Cancer Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others •Biliary Tract Cancer Therapies- Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others. Get the latest on Biliary Tract Cancer therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Biliary Tract Cancer Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Table of Content 1.Introduction 2.Executive Summary 3.Biliary Tract Cancer: Overview 4.Pipeline Therapeutics 5.Therapeutic Assessment 6.Biliary Tract Cancer- DelveInsight's Analytical Perspective 7.Late Stage Products (Phase III) 8.Envafolimab: Alphamab Oncology 9.Drug profiles in the detailed report..... 10.Mid Stage Products (Phase II/III) 11.SMT-NK: SMT bio Co., Ltd. 12.Drug profiles in the detailed report..... 13.Mid Stage Products (Phase II) 14.HA121-28: CSPC ZhongQi Pharmaceutical Technology 15.Drug profiles in the detailed report..... 16.Early Stage Products (Phase I) 17.ZKAB001: Lee's Pharmaceutical Limited 18.Drug profiles in the detailed report..... 19.Preclinical and Discovery Stage Products 20.Drug name: Company name 21.Drug profiles in the detailed report..... 22.Inactive Products 23.Biliary Tract Cancer Key Companies 24.Biliary Tract Cancer Key Products 25.Biliary Tract Cancer- Unmet Needs 26.Biliary Tract Cancer- Market Drivers and Barriers 27.Biliary Tract Cancer- Future Perspectives and Conclusion 28.Biliary Tract Cancer Analyst Views 29.Biliary Tract Cancer Key Companies 30.Appendix List of Top Selling Market Research Reports in 2024 carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market stem cell market- https://www.delveinsight.com/report-store/stem-cell-market surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: info@delveinsight.com Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.Levis throws 2 TD passes to help Titans outlast Texans 32-27
Philadelphia takes on Vegas after overtime winChiefs hold off pesky Panthers, win on last-second FG
NFL Week 12: Instant analysis from Patriots’ 34-15 loss to Dolphins - Pats Pulpit